Macro Economy - The Ministry of Industry and Information Technology (MIIT) issued an action plan for the high-quality development of industrial internet platforms from 2026 to 2028, aiming to have over 450 influential platforms and more than 120 million industrial devices connected by 2028, with a platform penetration rate exceeding 55% [2] - MIIT held the 18th manufacturing enterprise symposium, emphasizing active participation in industry rule-making and self-regulation to promote a win-win environment and protect industry development [2] Investment News - On January 13, A-shares experienced a collective pullback, with the Shanghai Composite Index ending a 17-day winning streak, closing down 0.64%. The total trading volume in Shanghai, Shenzhen, and Beijing reached 3.7 trillion, setting a new historical record [5] - The Hang Seng Index rose by 0.9%, with the Hang Seng Technology Index increasing by 0.11%. Pharmaceutical stocks performed well, with WuXi AppTec rising over 8% and WuXi Biologics nearly 6%. The H-share listing of Zhaoyi Innovation saw a peak increase of over 53% on its first day, closing with a 37.53% rise, valuing the company at 155.2 billion HKD [5] - As of January 12, the management scale of ETF products under Huaxia Fund officially surpassed 1 trillion RMB, reaching 1,016.424 billion RMB, making it the first domestic ETF manager to enter the "trillion club" [5] - Approximately 130 A-share listed companies have disclosed their 2025 performance forecasts, with around 70 companies expecting positive results, including profit increases and recoveries [5] - A total of 186 listed companies have been subject to concentrated research by public funds and brokerages, with the number of research instances reaching 220, indicating strong interest in popular stocks like Aipeng Medical and Entropy Technology [5] Company Movements - Guizhou Moutai is establishing a dynamic adjustment mechanism for retail prices based on market orientation, aiming for a "market-following, relatively stable" self-operated system [6] - The "Dead or Alive APP" will officially adopt the global brand name Demumu in its upcoming new version [7] - Alibaba Cloud has completed further strategic investment in ZStack, achieving a controlling stake, and plans to create a standardized and inclusive cloud-edge integrated solution [7] - DeepSeek published a new paper on conditional memory for large language models, co-authored with Peking University [7] - Huaxia Happiness expects a net loss of 16 billion to 24 billion RMB in 2025, with potential delisting risk warnings for its stock [8] - Zhongwen Online anticipates a net loss of 580 million to 700 million RMB in 2025, as its overseas short drama business is still in the investment phase [8] - Luxshare Precision has terminated its acquisition of the business asset package held by India's Wingtech [8]

Group 1 - The Ministry of Industry and Information Technology (MIIT) has issued an action plan for the high-quality development of industrial internet platforms from 2026 to 2028, focusing on four key actions: platform cultivation, data intelligence enhancement, large-scale application, and ecosystem support [1][10][25] - By 2028, the plan aims to establish a multi-layered platform system with over 450 influential platforms, enhance resource connectivity, and achieve a platform penetration rate of over 55% [10][28] Group 2 - Eight departments, including the Ministry of Civil Affairs, have jointly released 14 measures to promote the development of the silver economy, emphasizing technology empowerment in elderly care services and encouraging the development of elderly care robotics [2][5][20] - The measures aim to support the establishment of operating entities in elderly care services and promote technological advancements to assist elderly individuals with declining physical functions [5][20] Group 3 - The National Development and Reform Commission (NDRC) is set to lead the formulation of the "14th Five-Year" plan for circular economy development, focusing on solid waste management and addressing long-standing industry challenges [3][21] - The action plan aims to fill institutional gaps and enhance the effectiveness and innovation of solid waste management strategies [3][21] Group 4 - Shanghai has introduced 28 policies to enhance the synergy between consumption and service industry development, targeting key sectors such as finance, information services, and transportation [4][22][23] - The measures are designed to optimize supply and expand consumption, promoting mutual growth between service quality improvement and consumption expansion [22][23] Group 5 - Contemporary Amperex Technology Co., Ltd. (CATL) has signed a significant procurement agreement with Rongbai Technology for lithium iron phosphate materials, with a total sales amount exceeding 120 billion yuan, expected to positively impact future business performance [9][12][31] - The partnership includes a strategic investment in Fulian Precision Engineering, which will utilize the funds to develop high-end energy storage lithium iron phosphate projects [9][27][31] Group 6 - The price of lithium carbonate futures has surged significantly at the beginning of 2026, with the main contract exceeding 170,000 yuan per ton, marking a 37.25% increase since the end of 2025 [14][33] - This price increase is attributed to the demand surge following the reduction of export tax rebates, indicating a strong market response [14][33]

Core Viewpoint - The article discusses the evolving landscape of the Chinese healthcare sector, particularly in the context of the upcoming JP Morgan Healthcare Conference, highlighting the diversification of Chinese companies and their strategic positioning in the global market [4][29]. Group 1: Conference Overview - The JP Morgan Healthcare Conference is the largest and most informative international healthcare investment and business development meeting, scheduled for January 12-15, 2026, in San Francisco [4]. - Approximately 22 Chinese companies are participating, categorized into four distinct roles: transaction-oriented innovative drug companies, disclosure companies at commercialization or regulatory milestones, supply-side platforms for global R&D and production outsourcing, and device companies focusing on efficiency and international expansion [4]. Group 2: Supply-Side Platforms - Supply-side platform companies are becoming essential in the global innovation chain, as they focus on delivering stable and efficient R&D and production capabilities, especially during periods of increased volatility in innovative drug companies [6][8]. - WuXi Biologics is shifting its focus from project quantity to project quality, emphasizing capacity utilization and long-term contract stability as key indicators of its value in the global biopharmaceutical supply chain [8]. Group 3: Cross-Border Licensing and Outbound Companies - The pricing logic for Chinese innovative drugs in cross-border licensing has evolved, with a focus on the overall deliverable capabilities rather than just the individual molecules [14]. - Companies like Kelun-Blotech and BaiLi Tianheng are exemplifying this trend by integrating their platforms into global R&D systems and establishing long-term collaborations with multinational pharmaceutical companies [16][18]. Group 4: Regulatory and Commercialization Companies - Companies that have accumulated clinical data and registration progress are transitioning towards verifiable sales and profit curves, shifting their valuation logic from future expectations to tangible cash flows [19]. - Zai Lab and Antengene are in the early commercialization stages, with their success hinging on their products' acceptance in clinical settings and the speed of prescription growth [21][23]. Group 5: Medical Device Companies - Mindray Medical is recognized for its comprehensive coverage of hospital workflows, with a focus on multi-product synergy rather than single-device performance, which is crucial for establishing long-term customer relationships [26]. - MicroPort Scientific is navigating a challenging environment where operational efficiency and cash flow management are critical for sustaining long-term clinical validation and international expansion [28]. Group 6: Industry Trends and Insights - The Chinese healthcare sector is transitioning from a phase of visibility to one of selection, where companies must clearly define their positions and deliverables in a high-intensity global exchange [29]. - The differentiation among Chinese companies in the global system is accelerating, with a clear divide between transaction-oriented innovative drug companies and those that have crossed critical regulatory milestones, focusing on verifiable growth [31].

Group 1: Market Overview - The A-share market experienced a collective pullback on January 13, with the Shanghai Composite Index down 0.64%, ending a 17-day winning streak, while the Shenzhen Component Index fell 1.37% and the ChiNext Index dropped 1.96% [1] - The trading volume in the Shanghai, Shenzhen, and Beijing markets exceeded 3.6 trillion yuan, marking a slight increase from the previous day and setting a new historical high [1] Group 2: AI Medical Sector - The AI medical sector continues to thrive, with significant gains; the Hong Kong medical ETF (159137) surged by 3.44% and reached a near-limit-up level, while the largest A-share medical ETF (512170) hit a three-month high with a peak increase of 3.67% [4][6] - AI medical concept stocks saw substantial increases, with Ark Health rising over 76% after announcing a collaboration with Tencent Health on an "AI + chronic disease management" plan [4][8] Group 3: Banking Sector - The banking sector showed resilience, with several banks like Ningbo Bank and Hangzhou Bank seeing gains of over 4% and 3% respectively, while the top banking ETF (512800) rose by 0.37% [11][13] - The first bank executive buyback announcement of 2026 was made by Chongqing Rural Commercial Bank, indicating confidence in the company's fundamentals [13] - Historical data suggests that the banking sector tends to perform well before the Spring Festival, with an average absolute return of 4.4% [16] Group 4: Commercial Aerospace Sector - The commercial aerospace sector faced volatility, with the general aviation ETF (159231) experiencing a significant drop of 7.27%, despite a net inflow of 46 million yuan on the same day [18][19] - The sector's performance has been mixed, with 44 out of 50 component stocks declining, while some stocks like Tianyin Electromechanical and Haige Communication saw gains [18] Group 5: Future Outlook - Analysts suggest that the current market liquidity is ample, and thematic trading is expected to continue, with a focus on the "Musk Chain" and non-bank financial investment opportunities [3] - The market is anticipated to exhibit structural opportunities, with a theme-driven approach and rapid capital rotation among different industry lines [3]

Market Overview - The three major indices collectively adjusted, with the Shenzhen Component Index falling over 1% and the ChiNext Index dropping nearly 2%. The trading volume in the Shanghai and Shenzhen markets reached 3.65 trillion yuan, an increase of 49.6 billion yuan from the previous trading day [1][9]. - A-share market has shown strong performance since the beginning of the year, with abundant liquidity and record-high trading volumes. Investor optimism for the first half of 2026 is supported by frequent catalysts in the technology sector, including IPOs in AI and semiconductors, and innovations in AI applications [10]. Sector Performance - The pharmaceutical sector led the gains today, with the Innovation Drug ETF (517110) rising by 2.69% and the Biopharmaceutical ETF (512290) increasing by 1.57%. This is attributed to several overseas innovative drug collaborations and catalysts [13][14]. - AI healthcare is experiencing global catalysts, with OpenAI integrating health dialogue features into ChatGPT, enhancing user access to health data [14]. Gold Market Insights - Spot gold prices in London surpassed $4,600 per ounce, with Citigroup raising its 0-3 month target price to $5,000 per ounce. State Street indicated a greater than 30% chance of gold hitting this target this year [11]. - Geopolitical risks have increased, driving up gold's risk premium. The U.S. administration is discussing potential interventions in Iran, which could escalate conflicts in the Middle East [12][11]. Electricity and Infrastructure - The electricity sector showed relative strength, driven by the upcoming National Grid meetings and ongoing power supply issues in North America. The approval of high-voltage direct current projects has accelerated since mid-2025, indicating strong demand for electricity infrastructure [15][6]. - The global energy transition is creating a need for enhanced electricity grid construction to support renewable energy integration, particularly in underdeveloped regions [15]. Investment Recommendations - Investors are advised to consider the China Securities A500 ETF (159338) for broad exposure to leading companies across various sectors, and to adopt a "dumbbell" strategy focusing on technology and dividends to balance growth and volatility [10]. - For gold investments, options include direct investment in physical gold and gold ETFs that cover the entire industry chain [12]. Future Outlook - The market is expected to continue its upward trend due to ample liquidity and high demand in the AI sector. However, a potential phase of correction may occur following rapid market gains [10]. - The pharmaceutical sector's global competitiveness is strengthening, with upcoming earnings announcements from innovative drug companies anticipated to act as catalysts [14].

Group 1 - The core viewpoint of the report indicates that northbound capital returned to net inflow in the fourth quarter, primarily flowing into sectors such as non-ferrous metals, electronics, and electric equipment, while experiencing slight outflows from the main board [2][4] - In the first week of January, financing funds saw significant net inflows, contributing important incremental capital to the market, suggesting that the A-share market is likely to continue its upward trend [2][4] - The report highlights that the main investment themes for January will remain focused on technology and cyclical stocks, with a recommendation for large-cap growth stocks [2][4] Group 2 - Northbound capital recorded a net inflow of 9.5 billion yuan in the fourth quarter, accounting for 2.63% of the A-share circulating market value [4][9] - The sectors that attracted the most northbound capital included non-ferrous metals (24.5 billion yuan), electric equipment (17 billion yuan), and electronics (15.8 billion yuan), while the largest outflows were seen in pharmaceuticals (-16 billion yuan), food and beverage (-15.3 billion yuan), and non-bank financials (-9.7 billion yuan) [4][9] - The top three stocks with net purchases from northbound capital were Ningde Times (12.1 billion yuan), Luxshare Precision (6 billion yuan), and Weichai Power (5.2 billion yuan), while the largest net sales were from Kweichow Moutai (-8.6 billion yuan), WuXi AppTec (-5 billion yuan), and BYD (-4.8 billion yuan) [4][9][12] Group 3 - The report notes that the liquidity indicators show a decrease in public fund issuance to 9.61 billion yuan, while ETF net subscriptions increased to 9.73 billion yuan, and financing net purchases rose to 857.75 billion yuan [3][26] - The average daily trading volume of A-shares increased to 28,519.51 million yuan, indicating a shift in the secondary market towards net inflows [3][4] - The report also mentions that the financing balance has risen, with net purchases of financing funds indicating a positive shift in market sentiment [4][26]

Core Viewpoint - WuXi AppTec, a leading CRO, is expected to achieve revenue of approximately 45.456 billion yuan in 2025, representing a year-on-year growth of 15.84%, and a net profit of about 19.151 billion yuan, reflecting a year-on-year increase of approximately 102.65% [1][39]. This significant performance has sparked enthusiasm in the CRO sector, although it alone cannot sustain the overall pharmaceutical market's momentum [39]. AI Medical Sector - The recent surge in AI applications is evolving towards the AI medical sector, indicating a clear trend in the industry [40][42]. - OpenAI has acquired the medical technology startup Torch and launched several enterprise-level products for healthcare institutions, marking its commitment to the "AI + healthcare" business [41]. - NVIDIA and Eli Lilly announced a $1 billion investment to establish a joint research lab in the San Francisco Bay Area over the next five years, aimed at accelerating AI applications in the pharmaceutical industry [41]. AI Pharmaceutical Sector - AI technology can accelerate target discovery, compound screening, and preclinical research, shortening development cycles by 50%-80% and reducing costs by 30%-50% [8][45]. - WuXi AppTec has developed an AI-driven small molecule drug discovery platform, Chemistry42, integrating AI models with molecular simulation technology [10][46]. - Other leading CROs like Mediso and Yiqiao Shenzhou are also making significant progress, with Mediso reducing the development cycle of kinase inhibitors from 12 months to 3 months and cutting costs by 70% [12][48]. Innovative Drug Sector - Companies like Hongbo Pharmaceutical and Chengdu XianDao are making notable advancements in technology and performance [14][50]. - Hongbo Pharmaceutical's AI peptide drug design platform has received national software copyright certification, processing 500,000 data entries daily and improving drug-like property prediction accuracy by 15% [16][52]. - Chengdu XianDao reported a revenue increase of 23.98% and a net profit increase of 208.34% in the first three quarters of the previous year [20][56]. AI Medical Imaging - AI-assisted imaging analysis enhances diagnostic accuracy and efficiency, representing a significant sub-sector [22][58]. - The current market size for AI pharmaceuticals is approximately 800-1,000 million yuan, with a projected compound annual growth rate of 68.5% from 2024 to 2028 [60]. - The AI medical imaging market is expected to reach approximately 15 billion yuan in 2025, with a year-on-year growth of about 101% [60]. Medical Information Technology - AI integration into medical information systems aims to achieve intelligent consultations, medical record quality control, and clinical decision support [63]. - Policies promoting AI-assisted diagnosis in grassroots medical institutions are expected to drive a new wave of growth in medical information technology [30][65]. Investment Opportunities - The AI medical sector can be categorized into three investment types: 1. AI medical imaging and medical information technology, suitable for conservative investors seeking stable cash flows [69]. 2. AI pharmaceuticals and surgical robots, appealing to growth-oriented investors [70]. 3. Brain-machine interfaces, attracting risk-tolerant investors due to their nascent market status [71].

伴随着2025年年报披露的拉开序幕，热门赛道的核心公司业绩是否能持续支撑高估值，成为许多基本面投资者关注的焦点。 披露时间来看，业绩预告早于业绩快报，早于定期报告。以年报为例，①年度业绩预告于1月31日前披露，沪市、深市主板、创业板公司若出现净利润亏 损、扭亏为盈、净利润同比变动±50%以上、净资产为负（深市主板、创业板）必须强制披露；②业绩快报于2月底前披露，其中深市中小板、创业板公 司，若年报预约披露时间为3-4月，需强制发布年度业绩快报。沪市主板、深市主板公司可自愿披露，非强制；③年报正式披露介于1月-4月，其中3 月-4 月为集中披露期。 | | 25 年 1 月 | 25年２月 | 25年3月 | 25年4月 | | --- | --- | --- | --- | --- | | 2024 年报 业绩预告数量 | 2759 | ব | 32 | 75 | | 2024 年报 业绩快报数量 | 74 | 886 | 114 | 80 | | 2024 年报 定期报告数量 | | ટર | 964 | 4408 | 而从实务效果看，以Go-Goal每季度业绩超预期公司做成的组合看，2012年至今，业绩超 ...

Group 1 - WuXi AppTec (药明康德) is a leading global pharmaceutical R&D outsourcing company with a comprehensive layout in AI healthcare, integrating AI technology throughout the drug development process [1] - The AI drug discovery platform developed by WuXi AppTec utilizes machine learning to analyze vast compound data, significantly shortening the early development cycle of small molecules and biologics [1] - The platform has been applied in new drug development projects for oncology and neurodegenerative diseases [1] Group 2 - Aier Eye Hospital (爱尔眼科) is a leading domestic eye care chain focusing on the intelligent upgrade of the entire eye diagnosis and treatment process through AI [2] - The AI fundus screening system developed by Aier can accurately identify common eye diseases with an accuracy rate exceeding 95%, implemented in over a thousand grassroots eye clinics and health check centers nationwide [2] - The company also utilizes AI technology to create personalized correction plans for myopia patients and enhance the precision and safety of surgeries [2] Group 3 - Kanglong Chemical (康龙化成) is a core player in the domestic pharmaceutical R&D outsourcing sector, leveraging AI technology to enhance R&D service efficiency [3] - The AI drug development platform integrates molecular simulation and machine learning, reducing compound screening cycles from months to weeks [3] - AI is also used to construct disease models and simulate drug metabolism processes, improving data accuracy and reducing animal usage [3] Group 4 - Tigermed (泰格医药) is a leading clinical trial CRO in China, focusing on the intelligent transformation of the entire clinical trial process through AI [4] - The AI clinical trial management system enables intelligent project initiation, patient recruitment, and data management, improving recruitment efficiency by over 30% [4] - AI algorithms are employed for real-time monitoring of clinical trial data, providing precise risk warnings and decision-making support for pharmaceutical companies [4] Group 5 - Kelaiying (凯莱英) is a global leader in the pharmaceutical CDMO sector, applying AI technology to enhance drug production and R&D [5] - AI algorithms are used to design optimal chemical synthesis pathways, reducing production costs and enhancing safety and yield [5] - The company has developed an AI drug R&D platform to predict the physicochemical properties and biological activity of compounds, aiding in the rapid selection of candidate drug molecules [5] Group 6 - Meinian Health (美年健康) is a leading health checkup company in China, with AI healthcare as a core driver for upgrading its services [6] - The AI intelligent health check system covers the entire process from appointment scheduling to health report interpretation, with AI imaging diagnosis achieving accuracy close to that of professional doctors [6] - The company integrates national health check big data to conduct chronic disease trend research, supporting public health decision-making [6] Group 7 - Zhaoyan New Drug (昭衍新药) is a leader in non-clinical safety evaluation of drugs, focusing on the intelligent upgrade of drug safety evaluation through AI [7] - The AI drug safety prediction platform integrates vast toxicology data and machine learning algorithms to predict potential toxicity of new drugs early [7] - AI technology is also used for intelligent monitoring of experimental animals, enhancing data accuracy and reliability [7] Group 8 - BGI Genomics (华大基因) is a leading global player in the field of gene sequencing, deeply integrating AI technology with gene sequencing [8] - AI algorithms are applied to analyze gene sequencing data, significantly improving the efficiency and accuracy of genetic disease diagnosis [8] - The company has developed a big data platform to support precision medicine and drug development through AI analysis of vast genetic data [8] Group 9 - Tongce Medical (通策医疗) is a leading domestic dental care chain focusing on the intelligent upgrade of dental diagnosis and treatment through AI [9] - The AI dental imaging diagnosis system can automatically analyze dental CT and panoramic images, assisting dentists in making accurate diagnoses [9] - The company also utilizes AI technology to optimize patient appointment and triage systems, enhancing patient flow and reducing wait times [9] Group 10 - Haoyuan Pharmaceutical (皓元医药) is a core player in the domestic pharmaceutical reagents and raw materials sector, focusing on intelligent upgrades in drug and reagent development through AI [10] - The AI molecular design platform significantly shortens the discovery cycle of lead compounds in drug development [10] - AI technology is also used to optimize inventory management, reducing costs and improving supply chain efficiency [10] Group 11 - Jiuzhou Pharmaceutical (九洲药业) is an important player in the domestic CDMO sector, focusing on the intelligent upgrade of drug production and R&D through AI [11] - AI algorithms are utilized to design optimal chemical synthesis pathways, enhancing yield and reducing production costs [11] - The company has developed an AI drug R&D platform to predict the biological activity and pharmacokinetic properties of compounds [11] Group 12 - KingMed Diagnostics (金域医学) is a leading third-party medical testing company in China, with AI healthcare applications throughout the testing process [12] - The AI data analysis system can automatically analyze vast testing data, quickly identifying abnormal indicators and generating reports [12] - The company also integrates national testing big data to conduct epidemiological research, supporting public health prevention efforts [12] Group 13 - Dian Diagnostics (迪安诊断) is a leading third-party medical diagnostic service provider, with AI healthcare as a core driver for enhancing diagnostic capabilities [13] - The AI diagnostic platform covers multiple fields, achieving over 90% accuracy in identifying tumor cells and infectious lesions [13] - AI technology is also used to optimize testing processes, improving laboratory throughput and efficiency [13] Group 14 - Chengdu XianDao (成都先导) is a leading new drug development company, deeply integrating AI technology with its core DNA-encoded compound library business [14] - AI algorithms are used to design DNA-encoded compound libraries, significantly improving screening efficiency and hit rates [14] - The company has developed a cloud computing platform for AI drug R&D, providing intelligent services to global pharmaceutical companies [14] Group 15 - Sanbo Brain Science (三博脑科) is a specialized medical service institution in the field of neurosurgery, with AI applications in both healthcare and brain-computer interface technology [15] - The AI neuroimaging diagnosis system can automatically analyze brain CT and MRI images, assisting in diagnosing neurological diseases [15] - The company collaborates with research institutions to conduct clinical studies on brain-computer interfaces, helping patients regain motor function [15] Group 16 - Innovation Medical (创新医疗) is a comprehensive medical service enterprise focusing on intelligent upgrades in rehabilitation and orthopedic diagnosis through AI [16] - The AI rehabilitation assessment system collects patient movement data to automatically evaluate rehabilitation effectiveness and adjust training plans [16] - AI technology is also used to analyze X-ray and CT images for orthopedic diagnosis, enhancing the precision of surgical planning [16]

Core Viewpoint - The pharmaceutical sector, particularly companies integrating AI technologies, has shown significant growth, with Ark Health experiencing a surge of over 76% in stock price, while WuXi AppTec and WuXi Biologics led the blue-chip stocks with notable gains [2][8]. Group 1: Market Performance - The Hang Seng Index rose by 0.9% to close at 26,848.47 points, with a total market turnover of HKD 315.19 billion, an increase from HKD 306.22 billion in the previous trading day [2]. - Among the constituents of the Hang Seng Index, 53 stocks increased while 33 declined, with WuXi AppTec rising by 8.30% and WuXi Biologics by 5.85% [4]. - Notable stock performances included Alibaba, which increased by 3.63%, and China Life, which rose by 3.51% [4]. Group 2: Company Highlights - Ark Health's stock opened with a peak increase of 76.37%, closing at HKD 3.93 per share, marking a daily increase of 65.8% due to its collaboration with Tencent Health in the "AI + Chronic Disease Management" sector [8][9]. - WuXi AppTec's stock price surged by 9.66% to close at HKD 120 per share, driven by a positive earnings forecast indicating a projected net profit growth of approximately 102.65% for 2025 [10][12]. - WuXi Biologics also saw a significant increase, with a maximum rise of 6.92%, closing at HKD 39.78 per share, as the company prepares to present at the 44th Annual J.P. Morgan Healthcare Conference [16][17]. Group 3: Financial Projections - WuXi AppTec's earnings forecast includes an expected revenue of approximately HKD 45.46 billion for 2025, reflecting a year-on-year growth of about 15.84%, with adjusted net profit projected at HKD 14.96 billion, a 41.33% increase [12][13]. - WuXi Biologics anticipates signing a record 209 new projects in 2025, with a focus on expanding its commercial pipeline and maintaining a positive outlook for revenue growth in 2026 [20].